INTRODUCTION
The Nigerian pharmaceutical manufacturing industry is believed to be underdeveloped (Erhun, Babalola & Erhun, 2001; Olugbade 2005 ). Its total output accounts for approximately 30% of the local pharmaceutical market (Okhamefe, 2006) . The main challenges in the industry include non-affordability of medicines (Erhun et al., 2001 ), drug counterfeiting (Erhun et al., 2001 ), poor dispensing ethics associated with a chaotic distribution network (Akunyili, 2007) , the absence of Good Manufacturing Practice (GMP) 1 and a virtual absence of an effective research and development (R&D) base (Ogunyemi, Ibiwoye & Oyatoye, 2011 ).
The World Health Organization (WHO) has reported that Nigeria has the highest drug prices in the world, and the only country where its citizens spend up to 23% of their income on medicines (Magaji, 2010; Mourik et al., 2010) . Citing the same WHO report Ogundipe (2010) observes that the average drug price in Nigeria is 82%
higher than the next country in a group of eight nations with the highest drug prices in the world. Ammon (2008) points out that until recently, Nigeria was one of the few countries in the world with a high prevalence of fake drugs. Further, an overriding challenge in the industry is a severe lack of capital (Garuba, Kohler & Huisman, 2009 ). Such weak capital structure undermines the capacity of firms in the industry to engage in R&D (Okhamefe, 2006) , acquire the requisite infrastructure to 1 For example Obinna 2010 reports that no Nigerian pharmaceutical company is certified by the WHO as conforming to the rules of Good Manufacturing Practice (GMP).
In-Licensing as a Business Strategy for (Akunyili, 2007) , and generally operate with reasonable profits.
Various scholarly works have been completed on the industry with the objective of providing a viable path for real and steady growth while in turn addressing many of the above-mentioned issues. For instance, scholars such as Eaton (2008) . This form of alliance involves a firm's contractual arrangement with another on an already established product to be marketed under the franchisor firm's trade name, in exchange for a fee or royalty. In effect, as noted by Sherman (2011) franchising is restrictive and tailors the franchisee to the rules of the franchisor. This means that franchising has no place for research toward the creation of a new product. In this form of alliance however, all parties maintain their corporate identities without forming a third organization.
Outsourcing as a variant of strategic alliance has also been considered for pharmaceutical firms in Nigeria (Osemene et al., 2012 Licensing which is essentially a form of outsourcing, involves the termed transfer of intellectual property of one firm to the other or others for a fee (Reepmeyer, 2006) .
However, unlike generic outsourcing, licensing is never contracted on an ad hoc basis. There are two variants of licensing namely in-licensing and out-licensing.
Where there is an agreement such that the expertise of one is used to develop or process the products of others, it is in-licensing. On the other hand, where a firm transfers or licenses its intellectual property to another to develop for the licensee's own use at a fee, the firm is out-licensing such property (Reepmeyer 2006 The features of in-licensing and outsourcing as shown in Table 1 are almost the same and show that the two types of alliances are more advantageous than the other forms of strategic combinations. This is because they are the only forms of 
THE RESEARCH QUESTION
The primary aim of the proposed research is to develop an appropriate framework of in-licensing alliances for the Nigerian pharmaceutical industry so as to produce an operational model for growth that may lead toward global competitiveness. Thus, the main research question is: Essentially, the research will not only explore existing theories and models of inlicensing and situate them in Nigeria's environment; it will look at the strategy within the context of the value chain and construct as well as develop a framework accordingly.
CONTRIBUTION TO EXISTING KNOWLEDGE
Existing knowledge on strategy initiatives in the Nigerian pharmaceutical industry is mostly drawn from baseline survey reports by global multilateral bodies and rating institutions whose conclusions are largely anecdotal 7 . Although in-licensing is a 7 Various studies have noted this as a major gap in available analyses on the Nigerian pharmaceutical In In In-Licensing Alliances Both primary and secondary data will be employed in the research. Secondary data will be obtained from books, periodicals, journals, research papers, doctoral research theses, archives, gazettes such as policy documents, electronic and scholarly internet sources. Primary data collection will be in the forms of telephone interviews, in-depth personal interviews, emails, text messages and questionnaire(s). 
THE LITERATURE REVIEW
The review of literature will examine extant works on in-licensing in a manner that will first elaborate on the concept as a form of licensing, separate it from the other licensing variant, namely out-licensing (Sanchez, 2004; Reepmeyer, 2006) and identify, as well as describe the different variables inherent in the topic. It will also examine the different scholarly perspectives on the subject, its different paradigms and relate them to the Nigerian context.
LICENSING THEORIES
There are no specific in-licensing theories; rather organizational behavior theories propounded by scholars to explain strategic alliances, explain the concept of inlicensing. The different views of these scholars will be identified and the benefits and pitfalls of each of these views will be analyzed. The relevance of these theories to this research work is in the exploration of the extent of their applicability to the Nigerian situation. The theories are briefly described below.
Resource-Dependency Theory
This theory is based on the economic axiom that resources are scarce. Grant (2001) and have argued that firms recognize comparative advantages others have regarding certain resources particularly intellectual resources, such that they find it more rewarding to ally with such firms in order to take advantage of such resources. (2006) have looked at strategic alliances as a means for firms to benefit from the economics of large scale production. By pooling resources together transaction costs are scaled down through the dynamics of large scale production.
Organizational Learning Theory
This theory looks at unique organizational cultures and how they shape cognition 
Relationship Marketing Theory
In-licensing agreements on product marketing between or among companies are often predicated upon marketing pedigrees of firms within specific markets. Morgan and Hunt (1994); Hunt, Arnett and Madhavaram (2006) and Ismail and Alsadi (2010) suggest that over time and with deliberate efforts, firms become established in specific markets in ways that make them masters of such markets. It thus becomes strategic for another firm to market its own product(s) through the established firm especially when considering cost of entry into a new market.
In 
IN-LICENSING PARADIGMS AND FRAMEWORKS
Scholars have identified different paradigms or models that firms have adopted toward applying this type of strategic alliance. The research will examine these models and consider them as reference points or benchmarks for the purpose of constructing a new model for the Nigerian pharmaceutical industry. These models or paradigms are briefly described below.
Specialty Pharmaceutical Model
Within the framework of this model of in-licensing, firms capitalize on the therapeutic- . This model will be discussed in detail to determine if Nigerian firms have the potential to acquire the capacity for a niche position in any given therapy.
Blockbuster Model
Some firms that are brand owners of blockbuster drugs, use in-licensing to limit the opportunistic behavior of generic hawks at the back end of a patent life. According to Gilbert, Henske and Singh (2003) firms do this by fashioning partnerships with other firms whereby the licensor uses the cheap labor costs of the licensee to lower production costs and thus contain generic competition after a product goes off patent.
Open Innovation Model
Rasmussen ( 
Clinical Phase Model
Schafer ( 
EXISTING FRAMEWORKS WITHIN THE NIGERIAN CONTEXT
This section will reiterate the basics of in-licensing and its models, against the pharmaceutical business environment in Nigeria. The Nigerian pharmaceutical business environment will be observed from the perspectives of biotechnology, capital, infrastructure and culture. In this way we can have a broad understanding of the extent to which Nigeria's local content of these factors conform to global trends.
This will essentially provide a basis for recommendations toward how increased value may be obtained through a restructuring of the value chain by way of an increased and more efficient use of in-licensing agreements.
THE NEED FOR A NEW FRAMEWORK FOR NIGERIA
There are several scholarly accounts on Nigeria's business environment and factors that make the application of globally acclaimed investment models difficult in Nigeria. 
SUMMARY AND AVENUE FOR FUTURE RESEARCH
The Nigerian business environment has some characteristics with which any holistic business strategy has to contend. These include poor infrastructures, unstable 
RESEARCH PLAN
In-depth review of literature will take place within a twelve month period, during which the questionnaire will be structured, pre-tested and finalized. This will be followed by the administration of the questionnaire which will be through a five-month period. Personal and telephone interviews will be done in the four geopolitical zones of Nigeria where pharmaceutical production is concentrated. These are the SouthWest, South-East, North-Central and the South-South regions. This will be done during the same period of administering the questionnaire. Collation of collected data will be followed by data analyses, writing of the manuscript and completion of the work.
RESEARCH TIMELINE
Time estimates that cover the entire research work, showing milestones and allotted time periods are presented below. Although this research work is expected to strictly follow the timeline, there may be adjustments in the time estimates due to unforeseen circumstances.
RESEARCH BUDGET
Some expenses are expected to be incurred in the process of data collection and processing. These include purchase of articles and electronic materials not available in the university's library facilities, questionnaire production and administration, interview administration, among others. Below are the cost estimates.
TABLE 3 Dissertation Research Budget
Item $
Travel expenses 2, 000
Sourcing secondary research materials 2, 000
Electronic sources and equipment administration 1, 000
Questionnaire production and duplication 625
Interview and questionnaire administration 2, 000
Hotel accommodation 2, 100
Four regional questionnaire collators' fees 1, 250
Sundry expenses 650

Total $11, 650
The research will be fully funded by the researcher. No grants or scholarships will be requested of outside agencies. No financial assistance is required or being 
RESEARCH PROPOSAL APPROVAL
The contemplated research proposed herein has been approved by the University and the student may commence the research immediately. The student is not to deviate from the proposed research unless expressly confirmed by both the Supervisor and the University in written form. 
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